VIDA is Awarded $3M to Train 725 Participants in Nursing Pathways

Translate to Spanish or other 102 languages!

School, City, State, and other officials are pictured at the presentation.This grant project will provide VIDA with the opportunity to train and upskill 725 participants in high demand nursing occupations and ultimately secure employment at a partner hospital. Courtesy Image
School, City, State, and other officials are pictured at the presentation.This grant project will provide VIDA with the opportunity to train and upskill 725 participants in high demand nursing occupations and ultimately secure employment at a partner hospital. Courtesy Image

Mega Doctor News

- Advertisement -

Valley Initiative for Development and Advancement (VIDA) is honored to be a recipient of The Nursing Expansion Grant from U.S. Department of Labor to continue enhancing professional pathways to nursing and addressing the labor shortage nursing professionals face in the care economy across the Texas-Mexico border. This grant project will provide VIDA with the opportunity to train and upskill 725 participants in high demand nursing occupations and ultimately secure employment at a partner hospital. VIDA is grateful to The U.S. Department of Labor for recognizing the value in education to build and sustain a competitive nursing workforce in our community.

“We are immensely thankful to U.S. Department of Labor, for selecting VIDA as one of 25 organizations nationwide, and the only one in Texas, to be awarded this $3 Million Nursing Expansion Grant. It is our continued priority to maximize human capital and promote economic mobility through relevant workforce training among our underserved demographic, especially in the healthcare industry. For this grant project, VIDA is partnering with 13 local area hospitals, 3 higher education training institutions, various community-based organizations, and both regional workforce development boards. The key to our proposed innovative strategy for addressing the allied health and nursing labor shortage across the Rio Grande Valley is partnerships, collaboration, and accountability. These funds will be utilized to implement virtual reality technology for nursing clinicals, increase the number of nursing instructors at partner training institutions, provide customized wraparound student support services to ensure program completion, and ultimate job placement at one of 13 partner hospitals” said Felida Villarreal, VIDA’s President & CEO.

About Valley Initiative for Development and Advancement

- Advertisement -

For nearly 28 years, VIDA has helped more than 6,000 economically disadvantaged valley residents successfully complete career training programs in target demand occupations and achieve self-sufficiency. Last year, VIDA served 534 participants with an average persistence rate of 94% and an average annual salary upon graduation of over $48,000! This is a true representation of human capital investment and aligning workforce skills with local industry demand. 

To learn more about VIDA, please visit www.vidacareers.org or call (956) 903-1900.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -